Studies include pharmacology, toxicology, pharmacokinetics, and metabolism — conducted under 21 CFR Part 58 (Good Laboratory Practice).

Key IND-enabling studies include:

• Acute and repeated-dose toxicity (rodent and non-rodent species)
• Genotoxicity and reproductive toxicity
• Safety pharmacology (cardiac, respiratory, CNS effects)
• Analytical and stability data for drug substance and formulation

These data form the foundation of the IND submission and must justify initiation of clinical trials. FDA reviewers from CDER’s pharmacology/toxicology divisions evaluate safety margins, dose selection, and study design.

3. The Investigational New Drug (IND) Application

IND submission allows legal shipment of an investigational drug across state lines for human use. The application is governed by 21 CFR Part 312 and contains three major components:

• Animal Pharmacology & Toxicology Data – evidence of safety for human exposure.
• Manufacturing Information – details of drug substance, formulation, and GMP controls.
• Clinical Protocols & Investigator Information – outlining study design, dosing, inclusion/exclusion criteria, and investigator qualifications.

FDA reviews the IND within 30 days of receipt. If no clinical hold is placed, the sponsor may begin Phase 1 trials. Communication during this phase is typically through pre-IND and Type B meetings.

4. Clinical Trial Phases (I–III)

Phase	Primary Objective	Typical Subjects	Approximate Size
Phase I	Safety, tolerability, pharmacokinetics	Healthy volunteers	20–100
Phase II	Preliminary efficacy, dose-ranging	Patients with target condition	100–300
Phase III	Confirm efficacy, monitor adverse events	Large patient population	300–3,000+

Each phase must comply with ICH E6(R3) Good Clinical Practice (GCP).

All data are collected under electronic systems validated per 21 CFR Part 11.

At the end of Phase III, a complete data package supports the New Drug Application (NDA) or Biologics License Application (BLA).

5. The New Drug Application (NDA)

Once sufficient safety and efficacy are demonstrated, sponsors submit an NDA under 21 CFR Part 314.

NDA sections follow the Common Technical Document (CTD) format (Modules 1–5):

• Module 1: Administrative and labeling information
• Module 2: Summaries (quality, nonclinical, clinical)
• Module 3: Quality (CMC data)
• Module 4: Nonclinical study reports
• Module 5: Clinical study reports

The submission is made electronically via FDA eCTD gateway.

The review clock under PDUFA (Prescription Drug User Fee Act) is typically 10 months for standard and 6 months for priority reviews.

6. The Abbreviated New Drug Application (ANDA) Pathway

The ANDA is the regulatory route for marketing generic versions of previously approved drugs (the “Reference Listed Drug” or RLD).

Unlike NDAs, ANDAs do not require repetition of nonclinical or clinical trials but must demonstrate bioequivalence (BE) to the reference product.

ANDA submissions must comply with 21 CFR Part 314 Subpart C and include:

• Full CMC data for drug substance and product.
• BE study results under fasting and fed conditions.
• Labeling identical to the RLD (except for manufacturer differences).
• Patent certifications (Paragraph I–IV) and exclusivity statements.

ANDA review timelines are governed by the Generic Drug User Fee Amendments (GDUFA).

A well-prepared BE study is the most critical determinant of approval success.

7. Bioequivalence (BE) Studies and FDA Expectations

FDA defines bioequivalence as the absence of significant difference in rate and extent of absorption when compared under similar conditions.

Typical BE parameters include:

• Pharmacokinetic (PK) metrics: C_max, T_max, AUC_0–t, AUC_0–∞
• Statistical acceptance limits: 90% CI within 80–125%
• In vitro dissolution profile similarity (f₂ ≥ 50)

FDA’s Orange Book identifies the RLD for BE comparison.

For complex generics (inhalers, injectables, transdermals), FDA requires additional in vitro and in vivo bridging studies to demonstrate therapeutic equivalence.

8. eCTD Submission and Technical Standards

Since 2018, all IND, NDA, and ANDA submissions must use the electronic Common Technical Document (eCTD) format.

FDA’s Electronic Submissions Gateway (ESG) serves as the central portal.

Validation of XML backbone, use of correct module numbering, and adherence to granularity standards (per FDA eCTD Technical Conformance Guide) are essential.

Errors in metadata, checksum, or cross-referencing frequently cause submission delays.

9. Pre-Submission and Type B Meetings

Communication with FDA throughout development improves approval success.

Key meeting types include:

• Pre-IND Meeting: Discuss preclinical data and Phase 1 design.
• End-of-Phase 2 Meeting: Review efficacy data before Phase 3 initiation.
• Pre-NDA or Pre-ANDA Meeting: Confirm content and structure of final submission.

Meetings are requested via the Formal Meetings Between FDA and Industry Guidance.

Well-documented meeting packages and clear minutes serve as regulatory evidence of alignment.

10. Post-Approval Commitments and Lifecycle Management

Approval does not mark the end of regulatory oversight. Sponsors must maintain ongoing compliance through:

• Annual reports (21 CFR 314.81)
• Post-marketing safety reporting (21 CFR 314.80)
• Manufacturing site changes (CBE-30, PAS)
• Stability monitoring and specification updates

ANDA holders must remain current with RLD labeling and submit supplements for changes. FDA expects electronic submission of all lifecycle amendments via eCTD.

11. FDA Review Divisions and Interactions

Different product categories are reviewed by specialized FDA centers:

• CDER: Drugs and generics
• CBER: Biologics and vaccines
• OGD: Office of Generic Drugs (ANDA review)
• OCP: Office of Combination Products

Understanding each division’s expectations — particularly for CMC and bioequivalence data — streamlines review and avoids deficiencies.

Common deficiencies cited in Complete Response Letters (CRLs) include inadequate dissolution testing, missing stability data, or incomplete facility readiness documentation.

12. Inspection Readiness During Application Review

Before approval, FDA conducts Pre-Approval Inspections (PAIs) to verify manufacturing and analytical readiness.

Typical focus areas:

• Validation of manufacturing process and analytical methods
• Training and data integrity compliance
• Material traceability and batch records
• Equipment qualification and environmental monitoring

Deficiencies can delay approval until Form 483 responses are satisfactorily closed.

13. Global Harmonization and Reliance Models

FDA participates in the International Council for Harmonisation (ICH) and Pharmaceutical Inspection Co-operation Scheme (PIC/S) to align data requirements.

Recent initiatives like Project Orbis and Mutual Recognition Agreements (MRA) with EMA promote parallel reviews and reduce duplication.

Sponsors adopting harmonized CTD formats benefit from faster multi-market submissions.

14. Future Trends – Digital Submissions and AI Integration

The next generation of regulatory submissions will leverage automation, artificial intelligence, and structured data analytics.

FDA’s Office of Digital Transformation is investing in cloud-based submission management and automated review tools.

Sponsors are encouraged to prepare for next-generation eCTD (v4.0) and structured content authoring (SCA) technologies to remain compliant and competitive.

15. Final Thoughts

Whether pursuing an IND for innovative therapy or an ANDA for cost-effective generics, success depends on scientific rigor, regulatory alignment, and transparent communication with FDA.

In 2026, sponsors that embrace digital submissions, lifecycle planning, and early regulatory engagement will navigate the IND/ANDA pathways more efficiently — achieving faster, compliant approvals that bring safe and effective medicines to patients worldwide.